Source: Eur Respir J, 54 (6) 1901929; 10.1183/13993003.01929-2019
Disease area: Airway diseases, Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Gregory B. Waypa, Paul T. Schumacker. Roles of HIF1 and HIF2 in pulmonary hypertension: it all depends on the context. Eur Respir J, 54 (6) 1901929; 10.1183/13993003.01929-2019

Member's Comments

No comment yet.

Related content which might interest you: Suppression of HIF2 signalling attenuates the initiation of hypoxia-induced pulmonary hypertension Source: Eur Respir J, 54 (6) 1900378; 10.1183/13993003.00378-2019 Year: 2019 RASSF1A regulates ROS-HIF axis in hypoxia driven pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: novel insights Year: 2016 Hypoxia-induced miR-130a is a novel repressor of BMPR2 gene expression in experimental pulmonary hypertension Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms Year: 2012 Altered expression of the Smad signalling pathway: implications for COPD pathogenesis Source: Eur Respir J 2006; 28: 533-541 Year: 2006 Functional upregulation of PRMT2 in chronic hypoxia-induced pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 721s Year: 2004 Selective inhibition of BET bromodomain and their effect on nuclear factor-kappa B activation in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Inhibition of the miRNA familiy miR-130 restores the expression of CDKN1A (p21) and ameliorates hypoxia-induced pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension: pathobiology Year: 2014 Stabilised ferroportin activity affects pulmonary vascular cells responses: implications for pulmonary hypertension Source: International Congress 2018 – Experimental research in pulmonary hypertension Year: 2018 A novel piperidine attenuates pulmonary arterial hypertension via regulating BMP2 and PTGS2 levels Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 The matrix-fibroblast interplay contributes to HIF-1 alpha pathway activation: a possible therapeutic target in idiopathic pulmonary fibrosis (IPF) Source: Virtual Congress 2020 – Elucidating the mechanisms underlying lung repair and exploring therapeutic strategies in vitro Year: 2020 Dual mechanism of platelet-derived growth factor (PDGF)-receptor: Contribution of vascular response to the pathogenesis of pulmonary hypertension (PH) Source: International Congress 2015 – Pulmonary hypertension: novel insights into the biology of the disease Year: 2015 Role and regulation of Jumonji C domain-containing histone demethylases 1A and 2B in pulmonary hypertension Source: International Congress 2016 – The nature of pulmonary hypertension Year: 2016 AntagomiR directed against miR-20a restores BMP signaling in hypoxia-induced pulmonary hypertension in vivo Source: Annual Congress 2011 - Molecular: pathology of infectious and inflammatory lung disease Year: 2011 Selective TSC1 deletion in smooth muscle activates mTOR signaling and induces pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015 Pharmacological activation of Nur77 enhances BMP signalling and inhibits vascular remodelling in pulmonary arterial hypertension Source: International Congress 2018 – Pathobiology of pulmonary hypertension Year: 2018 The modulatory effects of Nrf2 activators in a pulmonary arterial hypertension model Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension Year: 2020 The hypoxia-induced miR-130 increases proliferation of pulmonary arterial smooth muscle cells by targeting the tumour suppressor CDKN1A (p21) Source: Annual Congress 2013 –Pulmonary circulation: basic science Year: 2013 Role of Gremlin in pulmonary hypertension Source: Annual Congress 2012 - Contributing factors to pulmonary hypertension Year: 2012